Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
Gynecological cancers such as breast, ovarian, and endometrial carcinoma express receptors for luteinizing hormone-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST). These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid molecules consisting of a cytotoxic radical and a peptide hormone analogue as a carrier. These compounds have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the respective receptors. The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.
Engel
Jörg B
JB
Universitätsfrauenklinik Würzburg, Josef-Schneider-Strasse 4, 97080 Würzburg, Germany. joergbengel@hotmail.com
Schally
Andrew V
AV
Dietl
Johannes
J
Rieger
Lorenz
L
Hönig
Arnd
A
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D007987:Gonadotropin-Releasing Hormone / Q000737:chemistry / Q000633:toxicity; D006801:Humans; D015394:Molecular Structure; D036361:Peptide Hormones / Q000737:chemistry* / Q000633:toxicity*; D013379:Substrate Specificity; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology
D036361:Peptide Hormones; D007987:Gonadotropin-Releasing Hormone